Finance News

Stem Cell Therapy Market is estimated to be worth USD 8.5 Billion by 2030

The success of approved stem cell therapies has caused a surge in interest of biopharma developers in this field; many innovator companies are currently progressing proprietary leads across different phases of clinical development, with cautious optimism

Roots Analysis has announced the addition of “Global Stem Cells Market: Focus on Clinical Therapies, 2020–2030 (Based on Source (Allogeneic, Autologous); Origin (Adult, Embryonic); Type (Hematopoietic, Mesenchymal, Progenitor); Lineage (Amniotic Fluid, Adipose Tissue, Bone Marrow, Cardiosphere, Chondrocytes, Corneal Tissue, Cord Blood, Dental Pulp, Neural Tissue Placenta, Peripheral Blood, Stromal Cells); and Potency (Multipotent, Pluripotent))” report to its list of offerings.

There is a growing body of evidence supporting the vast applicability and superiority of treatment outcomes of stem cell therapies, compared to conventional treatment options. In fact, the unmet needs within this domain have spurred the establishment of many start-ups in recent years.

To order this 500+ page report, which features 185+ figures and 220+ tables, please visit this link

Key Market Insights

Over 280 stem cell therapies are under development, most of which are allogeneic products 
More than 50% of the pipeline candidates are in the mid to late phase trials (phase II and above), and allogenic therapies (majority of which are derived from the bone marrow) make up 65% of the pipeline.

70% of pipeline candidates are based on mesenchymal stem cells 
It is worth highlighting that the abovementioned therapies are designed to treat musculoskeletal (22%), neurological (21%) and cardiovascular (15%) disorders. On the other hand, hematopoietic stem cell-based products are mostly being evaluated for the treatment of oncological disorders, primarily hematological malignancies.

Close to 85% stem cell therapy developers are based in North America and Asia-Pacific regions
Within these regions, the US, China, South Korea and Japan, have emerged as key R&D hubs for stem cell therapies. It is worth noting that majority of the initiatives in this domain are driven by small / mid-sized companies

Over 1,500 grants were awarded for stem cell research, since 2015
More than 45% of the total amount was awarded under the R01 mechanism (which supports research projects). The NCI, NHLBI, NICHD, NIDDK, NIGMS and OD emerged as key organizations that have offered financial support for time periods exceeding 25 years as well.

Outsourcing has become indispensable to R&D and manufacturing activity in this domain 
Presently, more than 80 industry / non-industry players, based in different regions across the globe, claim to provide contract development and manufacturing services to cater to the unmet needs of therapy developers. Examples include (in alphabetical order) Bio Elpida, Cell and Gene Therapy Catapult, Cell Tech Pharmed, GenCure, KBI Biopharma, Lonza, MEDINET, Nikon CeLL innovation, Roslin Cell Therapies, WuXi Advanced Therapies and YposKesi.

North America and Asia-Pacific markets are anticipated to capture over 80% share by 2030
The stem cell therapies market is anticipated to witness an annualized growth rate of over 30% during the next decade. Interestingly, the market in China / broader Asia-Pacific region is anticipated to grow at a relatively faster rate.

To request a sample copy / brochure of this report, please visit this link    

Key Questions Answered

  • Who are the leading developers of stem cell therapies?
  • Which types of clinical conditions can be treated using stem cell therapies?
  • Which cell lineages and types of stem cells are commonly used for therapy development?
  • Who are the key contract service providers engaged in this domain?
  • How is the current and future market opportunity likely to be distributed across key market segments?
  • What kind of key commercialization strategies are being used by stem cell therapy developers?

The USD 8.5 billion (by 2030) financial opportunity within the stem cell therapies market has been analyzed across the following segments:

  • Source of stem cell 
    • Allogeneic
    • Autologous
  • Origin of stem cell
    • Adult
    • Embryonic
  • Type of stem cell
    • Hematopoietic
    • Mesenchymal
    • Progenitor
    • Others
  • Lineage of stem cell 
    • Adipose Tissue
    • Bone Marrow
    • Cord Blood
    • Others
  • Route of Administration
    • Intraarticular
    • Intracoronary
    • Intramuscular
    • Intramyocardial
    • Intrathecal
    • Intravenous
    • Surgical Implantations
    • Others
  • Therapeutic Area
    • Autoimmune / Inflammatory Disorder
    • Cardiovascular Disorders
    • Metabolic Disorder
    • Musculoskeletal Disorders
    • Oncological Disorders
    • Neurological Disorders
    • Ophthalmic Disorders
    • Others
  • End Users
    • Ambulatory Surgery Centers
    • Hospitals
    • Specialty Clinics
  • Key Geographies
    • North America
    • Europe
    • Asia-Pacific and Rest of the World

The report features inputs from eminent industry stakeholders, according to whom stem cell therapies are currently considered to be a promising alternatives for the treatment of a myriad of disease indications, with the potential to overcome challenges associated with conventional treatment options. The report includes detailed transcripts of discussions held with the following experts:

  • William L Rust (Founder and Chief Executive Officer, Seraxis)
  • Xuejun Huang Parsons (Chief Executive Officer, Xcelthera)
  • Michel Revel (Co-Founder and Chief Scientist, Kadimastem) and Galit Mazooz-Perlmuter (Director, Business Development, Kadimastem)
  • Kikuo Yasui (Director and Chief Operating Officer, Heartseed
  • Gustav Steinhoff (Director and Chairman, Department of Cardiac Surgery, University of Rostock)
  • Gilles Devillers (President, Bio Elpida)
  • Fiona Bellot (Business Development Manager, Roslin Cell Therapies)
  • David Mckenna (Professor and American Red Cross Chair in Transfusion Medicine, University of Minnesota)
  • Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)
  • Mathilde Girard (Department Leader, Cell Therapy Innovation and Development, YposKesi)

The research covers brief profiles of several companies (including those listed below); each profile features an overview of the company, financial information (if available), stem cell therapy portfolio and an informed future outlook.

  • Anterogen
  • Athersys
  • CHABiotech
  • Cytopeutics
  • Hope Biosciences
  • Japan Regenerative Medicine
  • Lineage Cell Therapeutics
  • Orchard Therapeutics
  • Osiris Therapeutics
  • Pluristem Therapeutics
  • Promithera Biosciences
  • Regenexx
  • Stempeutics Research
  • SCM Life Sciences

For additional details, please visit

or email [email protected]

You may also be interested in the following titles: 

  1. Stem Cell Therapy Contract Manufacturing Market, 2019-2030
  2. Antibody Drug Conjugates Market (5th Edition), 2019-2030
  3. Cell and Advanced Therapies Supply Chain Management Market, 2019-2030: Focus on Technological Solutions
  4. Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019 – 2030


Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
[email protected]


Stem Cells Market Analysis, Emerging Trends, Innovations and Growth Opportunities up to 2027

The latest release from SMI with title Stem Cells Market Research Report 2020-2027 (by Product Type, End-User/Application, and Regions/Countries) evaluates each segment of the Stem Cells market in detail so that readers can be guided about future opportunities and high-profit areas of the industry. In inclusion, it presents an encyclopedic study of important market dynamics, including Market Size, Share, Growth Initiators, Trends, Obstacles, Challenges, and opportunities.

In addition, the statistical investigation of the report focuses on product specifications, costs, capacity, marketing channels, and market players. Upstream raw materials, downstream demand analysis, and end-user industry listings have been systematically studied with vendors in this market. Product flows and distribution channels were also presented in this research report.

Download FREE Sample Copy of This Report:

The scope of the report extends from market scenarios to price comparisons between key players, costs, and benefits in specific market regions. Numerical data is backed up with statistical tools such as SWOT analysis, BCG matrix, SCOT analysis, and PESTLE analysis. Statistics are presented in graphical format for a clear understanding of facts and figures.

The major manufacturers covered in this report:

CCBC, Vcanbio, Boyalife, Beikebiotech

Global Stem Cells Market Segmentations –

The segmentation chapter allows the reader to understand aspects of the global Stem Cells market such as products/services, available technologies, and applications. This chapter is written in a way that describes the years of development and the process that will take place in the years to come. Research reports also provide insightful information on emerging trends that can define the progress of these segments over the next few years.

Regional Insights of Stem Cells Market

In terms of region, this research report covers almost all the major regions across the globe such as North America, Europe, South America, the Middle East, and Africa, and the Asia Pacific. Europe and North America regions are anticipated to show an upward growth in the years to come. While Stem Cells Market in Asia Pacific regions is likely to show remarkable growth during the forecasted period. Cutting edge technology and innovations are the most important traits of the North America region and that’s the reason most of the time the US dominates the global markets. Stem Cells Market in the South, America region is also expected to grow in the near future.

Report Covers Impacts of COVID-19 to the market

The on-going pandemic has overhauled various facets of the market. This research report provides financial impacts and market disturbance in the Stem Cells market. It also includes analysis of the potentially lucrative opportunities and challenges in the foreseeable future. DataIntelo has interviewed various delegates of the industry and got involved in the primary and secondary research to confer the clients with information and strategies to fight against the market challenges amidst and after the COVID-19 pandemic.

Get Exclusive Discount Up to 50%:

Key Questions Answered in Report:

  1. What is the major factor which leads this market to the next level?
  2. What will the market Demand and what will be Growth?
  3. What are the latest opportunities for Stem Cells Market in the future?
  4. What are the strengths of the key players?
  5. What is the key to Stem Cells Market?

Global Stem Cells Market Industry Analysis assists clients with customized and syndicated reports of significant importance to the experts involved in data and market analysis. The report also calls for market-driven results that drive a feasibility study for customer needs. SMI guarantees validated and verifiable aspects of market data operating in real-time scenarios. Analytical studies are conducted to confirm customer needs with a thorough understanding of market capabilities in real-time scenarios.

In conclusion, the Stem Cells Market report is your trusted source for accessing research data that is expected to exponentially accelerate your business. This report provides information such as economic scenarios, benefits, limitations, trends, market growth rates, and figures. The SWOT analysis is also incorporated into the report along with the guess attainability survey and venture revenue survey.

Furthermore, the years considered for the study are as follows:

Historical year – 2014-2018
Base year – 2019
Forecast period – 2020 to 2027

If you have any special requirements please let us know we will offer you a report as you want.

Talk to Our Analyst for any Special Requirement/Customization of the report:

Explore By SJ